Search
Ovcon-35
35 ug ethinyl estradiol (estrogen) plus 0.4 mg norethindrone (progestin)
Indications:
1) prevention of pregnancy
2) treatment of hypermenorrhea
3) endometriosis
4) female hypogonadism
Contraindications:
pregnancy-category X
safety in lactation -
Dosage: Chewable oral tablet [2]
Pharmacokinetics: elimination: liver
Adverse effects:
1) common (> 10%)
- nausea, peripheral edema, breast enlargement, breast tenderness, anorexia, bloating
2) not common (1-10%)
- vomiting, diarrhea, increased libido, headache
3) uncommon (< 1%)
- intolerance to contact lenses, breast tumors, amenorrhea, alterations in mestrual flow, hypertension, thromboembolism, stroke, myocardial infarction, edema, depression, dizziness, anxiety, chloasma, melasma, rash, hyperglycemia, GI distress, increased serum triglycerides, increased LDL, cholestatic jaundice, increased susceptibility to Candida infection
Drug interactions:
- barbiturates, carbamazepine, cyclosporine, griseofulvin, penicillins, phenytoin, rifampin, tetracyclines
Interactions
drug adverse effects of estrogens
General
monophasic oral contraceptive
ethinyl estradiol/norethindrone (Junel Fe)
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Prescriber's Letter 11(2):suppl 2004
Components
ethinyl estradiol
norethindrone (Norlutate, Aygestin, Micronor)